Tiffany Nguyen1, Meghan E Sise2, Cindy Delgado3, Winfred Williams2, Peter Reese4,5, David Goldberg3. 1. Department of Medicine, University of Miami Miller School of Medicine, Miami, FL. 2. Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 3. Division of Digestive Health and Liver Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL. 4. Renal-Electrolyte and Hypertension Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 5. Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Abstract
BACKGROUND: Transplantation of kidneys from hepatitis C virus (HCV)-viremic donors into HCV-negative patients followed by direct-acting antiviral therapy was an important breakthrough to increase the number of life-saving kidney transplants. Data suggest that these transplants offer several benefits; however, it is unknown whether adoption of this practice has been shared equitably, especially among disadvantaged groups. METHODS: We evaluated United Network for Organ Sharing data on HCV-seronegative adult deceased-donor kidney transplant recipients from January 1, 2017, to June 12, 2020. We compared recipients of a kidney from an HCV antibody- (Ab-)/nucleic acid test- (NAT-), HCV Ab+/NAT-, and HCV NAT+ donor. The primary covariates were as follows: (1) race/ethnicity; (2) female sex; and (3) highest level of education. Models included variables associated with being offered an HCV NAT+ kidney. We fit mixed-effects multinomial logistic regression models with the center as a random effect to account for patient clustering. RESULTS: Of 48 255 adult kidney-alone deceased-donor kidney transplant HCV-seronegative recipients, 1641 (3.4%) donors were HCV NAT+-, increasing from 0.3% (January 2017-June 2017) to 6.9% (January 2020-June 2020). In multivariable models, racial/ethnic minorities, women, and those with less education were significantly less likely to receive a kidney from an HCV NAT+ donor relative to an HCV Ab-/NAT- and HCV Ab+/NAT- donor. The disparities were most pronounced among Hispanic and Asian patients with less educational attainment (grade school, high school, or some college/tech school). CONCLUSIONS: Despite an increase in transplants from HCV NAT+ donors, we found substantial racial/ethnic disparities in transplantation of these kidneys. These data highlight how the benefits of a scientific breakthrough are often made less available to disadvantaged patients.
BACKGROUND: Transplantation of kidneys from hepatitis C virus (HCV)-viremic donors into HCV-negative patients followed by direct-acting antiviral therapy was an important breakthrough to increase the number of life-saving kidney transplants. Data suggest that these transplants offer several benefits; however, it is unknown whether adoption of this practice has been shared equitably, especially among disadvantaged groups. METHODS: We evaluated United Network for Organ Sharing data on HCV-seronegative adult deceased-donor kidney transplant recipients from January 1, 2017, to June 12, 2020. We compared recipients of a kidney from an HCV antibody- (Ab-)/nucleic acid test- (NAT-), HCV Ab+/NAT-, and HCV NAT+ donor. The primary covariates were as follows: (1) race/ethnicity; (2) female sex; and (3) highest level of education. Models included variables associated with being offered an HCV NAT+ kidney. We fit mixed-effects multinomial logistic regression models with the center as a random effect to account for patient clustering. RESULTS: Of 48 255 adult kidney-alone deceased-donor kidney transplant HCV-seronegative recipients, 1641 (3.4%) donors were HCV NAT+-, increasing from 0.3% (January 2017-June 2017) to 6.9% (January 2020-June 2020). In multivariable models, racial/ethnic minorities, women, and those with less education were significantly less likely to receive a kidney from an HCV NAT+ donor relative to an HCV Ab-/NAT- and HCV Ab+/NAT- donor. The disparities were most pronounced among Hispanic and Asian patients with less educational attainment (grade school, high school, or some college/tech school). CONCLUSIONS: Despite an increase in transplants from HCV NAT+ donors, we found substantial racial/ethnic disparities in transplantation of these kidneys. These data highlight how the benefits of a scientific breakthrough are often made less available to disadvantaged patients.
Authors: David S Goldberg; Peter L Abt; Emily A Blumberg; Vivianna M Van Deerlin; Matthew Levine; K Rajender Reddy; Roy D Bloom; Susanna M Nazarian; Deirdre Sawinski; Paige Porrett; Ali Naji; Richard Hasz; Lawrence Suplee; Jennifer Trofe-Clark; Anna Sicilia; Maureen McCauley; Midhat Farooqi; Caren Gentile; Jennifer Smith; Peter P Reese Journal: N Engl J Med Date: 2017-04-30 Impact factor: 91.245
Authors: Tanjala S Purnell; Xun Luo; Deidra C Crews; Sunjae Bae; Jessica M Ruck; Lisa A Cooper; Morgan E Grams; Macey L Henderson; Madeleine M Waldram; Morgan Johnson; Dorry L Segev Journal: Transplantation Date: 2019-10 Impact factor: 4.939
Authors: Keith Luckett; Tiffany E Kaiser; Khurram Bari; Kamran Safdar; Michael R Schoech; Senu Apewokin; Tayyab S Diwan; Madison C Cuffy; Nadeem Anwar; Shimul A Shah Journal: J Am Coll Surg Date: 2018-12-23 Impact factor: 6.113
Authors: R A Wolfe; V B Ashby; E L Milford; A O Ojo; R E Ettenger; L Y Agodoa; P J Held; F K Port Journal: N Engl J Med Date: 1999-12-02 Impact factor: 91.245
Authors: James R Burton; Norah A Terrault; David S Goldberg; Roy D Bloom; Richard Gilroy; Julie K Heimbach; Robert S Brown; Gregory T Everson; Erin Rubin; Russ Wiesner; Elizabeth A Pomfret Journal: Transplantation Date: 2020-03 Impact factor: 4.939
Authors: David S Goldberg; Benjamin French; James D Lewis; Frank I Scott; Ronac Mamtani; Richard Gilroy; Scott D Halpern; Peter L Abt Journal: J Hepatol Date: 2015-11-25 Impact factor: 25.083
Authors: Vishnu S Potluri; David S Goldberg; Sumit Mohan; Roy D Bloom; Deirdre Sawinski; Peter L Abt; Emily A Blumberg; Chirag R Parikh; James Sharpe; K Rajender Reddy; Miklos Z Molnar; Meghan Sise; Peter P Reese Journal: J Am Soc Nephrol Date: 2019-09-12 Impact factor: 10.121
Authors: Deirdre Sawinski; Kimberly A Forde; Vincent Lo Re; David S Goldberg; Jordana B Cohen; Jayme E Locke; Roy D Bloom; Colleen Brensinger; Joe Weldon; Justine Shults; Peter P Reese Journal: Am J Kidney Dis Date: 2019-01-29 Impact factor: 8.860
Authors: Michael E de Vera; Michael L Volk; Ziphezinhle Ncube; Shawna Blais; Melissa Robinson; Nancy Allen; Ryan Evans; Jill Weissman; Pedro Baron; Arputharaj Kore; Charles Bratton; Gwendolyn Garnett; Thanh Hoang; Philip Wai; Rafael Villicana Journal: Am J Transplant Date: 2018-08-27 Impact factor: 8.086
Authors: Meghan E Sise; David S Goldberg; Jens J Kort; Douglas E Schaubel; Rita R Alloway; Christine M Durand; Robert J Fontana; Robert S Brown; John J Friedewald; Stacey Prenner; J Richard Landis; Melissa Fernando; Caitlin C Phillips; E Steve Woodle; Adele Rike-Shields; Kenneth E Sherman; Nahel Elias; Winfred W Williams; Jenna L Gustafson; Niraj M Desai; Brittany Barnaba; Silas P Norman; Mona Doshi; Samuel T Sultan; Meredith J Aull; Josh Levitsky; Dianne S Belshe; Raymond T Chung; Peter P Reese Journal: J Am Soc Nephrol Date: 2020-08-25 Impact factor: 10.121
Authors: Zoe A Stewart; Jeffrey Stern; Nicole M Ali; Harmit S Kalia; Karen Khalil; Srijana Jonchhe; Elaina P Weldon; Rebecca A Dieter; Tyler C Lewis; Nur Funches; Sudara Crosby; Monique Seow; Jonathan C Berger; Nabil N Dagher; Bruce E Gelb; Anthony C Watkins; Nader Moazami; Deane E Smith; Zachary N Kon; Stephanie H Chang; Alex Reyentovich; Luis F Angel; Robert A Montgomery; Bonnie E Lonze Journal: Transplant Direct Date: 2021-09-07
Authors: Asuncion Sancho; Eva Gavela; Julia Kanter; Sandra Beltrán; Cristina Castro; Verónica Escudero; Jonay Pantoja; Pablo Molina; Belen Vizcaíno; Mercedes González; Emma Calatayud; Ana Avila Journal: Front Med (Lausanne) Date: 2022-09-26